Education
About Us
Working with TipRanks
Follow Us
Formycon AG (DE:FYB)
XETRA:FYB
FYB Stock Chart & Stats
€23.00
€0.60(0.99%)
At close: 4:00 PM EST
€23.00
€0.60(0.99%)
Day’s Range― - ―
52-Week Range€19.02 - €54.90
Previous CloseN/A
Volume3.47K
Average Volume (3M)24.96K
Market Cap
€406.48M
Enterprise Value€389.40M
Total Cash (Recent Filing)€27.29M
Total Debt (Recent Filing)€10.21M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding17,672,928
10 Day Avg. Volume17,772
30 Day Avg. Volume24,962
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.01
Price to Sales (P/S)13.33
P/FCF Ratio-17.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.50Price Target Upside67.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Access And Recurring RevenueRegulatory approvals for FYB203 in the U.S., EU, and UK open immediate market access and establish ongoing payment and service revenue opportunities that can support commercial scale-up.
Partnerships And CommercializationExclusive licensing and supply agreement with a major partner for U.S. and Canada commercialization creates a clear revenue pathway through upfront and milestone payments while enabling access to established commercial and manufacturing resources.
Regulatory DevelopmentFYB208 achieved technical proof of similarity to the reference drug Dupixent, enabling approval without a comparative efficacy study and offering a faster, lower-cost regulatory route to market.
Bears Say
Analyst Confidence And Valuation RiskMaterial misses on revenue and earnings raise the risk of analyst downgrades and downward revisions to valuation assumptions, which could increase stock volatility and investor scrutiny.
Revenue ShortfallReported total revenue of €10.5 million fell short of the €15.0 million projection, signaling weaker-than-expected sales traction and creating pressure on near-term performance expectations.
Widening Net LossNet loss exceeded estimates, increasing cash burn and heightening the likelihood of near-term financing needs or accelerated cost-control measures.
Formycon AG News
FYB FAQ
What was Formycon AG’s price range in the past 12 months?
Formycon AG lowest stock price was €19.02 and its highest was €54.90 in the past 12 months.
What is Formycon AG’s market cap?
Formycon AG’s market cap is €406.48M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is Apr 23, 2026 which is in 82 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Nov 13, 2025. The company reported -€0.35 earnings per share for the quarter, missing the consensus estimate of -€0.04 by -€0.31.
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -€0.35 in its last earnings report, missing expectations of -€0.04. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in DE:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Formycon AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.19%
12-Months-Change
Fundamentals
Return on Equity
-34.48%
Trailing 12-Months
Asset Growth
-21.65%
Trailing 12-Months
Company Description
Formycon AG
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
FYB Stock 12 Month Forecast
Average Price Target
€38.50
▲(67.39% Upside)
Technical Analysis
Options Prices
Currently, No data available
---